Form 4: Pfizer CEO Albert Bourla Acquires Phantom Stock Units

Pfizer Chairman and CEO Albert Bourla acquired 911 phantom stock units through the company's deferred compensation plan.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 911 phantom stock units on April 14, 2026.
• The units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Each unit represents one phantom share of common stock valued at $27.11 per unit.
• Following this transaction, the reporting person holds a total of 760,090 units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial outlook.

Positives

• Demonstrates continued alignment of executive interests with company performance through deferred compensation participation.

Negatives

• None identified; this is a routine administrative transaction related to executive compensation plans.

Risks

• The value of the phantom stock units is tied to the future performance of Pfizer common stock.

Future Outlook

The units are settled in cash following the reporting person's separation from service, reflecting long-term retention and compensation strategy.

Management Comments

• The acquisition was made pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.

Industry Context

StockSavvy.ai notes that executive participation in deferred compensation plans is a standard corporate governance practice in the pharmaceutical industry to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The use of phantom stock units for executive compensation is consistent with practices at major pharmaceutical peers such as Merck, Bristol Myers Squibb, and Eli Lilly.
• The reporting of these transactions via Form 4 is standard regulatory compliance for all publicly traded U.S. companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation-related transaction.

Next Steps

• The reporting person will continue to hold these units until separation from service.

Key Dates

Keywords

Pfizer, PFE, Albert Bourla, Form 4, Insider Trading, Executive Compensation, Phantom Stock